Replimune Group Inc
NASDAQ:REPL
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its Industry Average (15.1), the stock would be worth $-78.92 (1 159% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -1.4 | $7.45 |
0%
|
| Industry Average | 15.1 | $-78.92 |
-1 159%
|
| Country Average | 16.7 | $-87.31 |
-1 272%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Replimune Group Inc
NASDAQ:REPL
|
593.3m USD | -1.4 | -1.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 715.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
407.9B USD | 24.4 | 97.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.9B USD | 24 | 25.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
178.6B USD | 19 | 21 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.4B USD | 29.7 | 29.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.8 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.4B USD | 11.8 | 17.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70.5B AUD | 16.5 | 35.8 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -83.5 | -61.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.8B EUR | 101.4 | 34.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.7 |
| Median | 16.7 |
| 70th Percentile | 23.6 |
| Max | 3 178 983.5 |
Other Multiples
Replimune Group Inc
Glance View
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. The company is headquartered in Woburn, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2018-07-20. The firm is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The firm applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The firm is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP1 (vusolimogene oderparepvec), RP2, and RP3. The firm is focused on Phase 2 clinical trials with its lead product candidate, RP1, in approximately 240 patients with a range of solid tumors.
